The Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Lincoln Pharmaceuticals to explain why segment-wise details were not submitted along with its financial results for the quarter ended 31 March 2025, under Regulation 33 of SEBI's listing rules. The company has not yet responded to the exchange's query. This is a routine clarification request related to disclosure compliance, not an enforcement action.
This is a procedural compliance query and is unlikely to affect the stock price significantly unless the company fails to respond or the matter escalates. Investors should wait for the company's clarification to see if there is any underlying issue with its segment reporting.